The valuation discount for the U.S. healthcare sector has disappeared, and investors are using it to hedge against AI trade risks
The healthcare sector has recently jumped to become one of the best-performing sectors in the S&P 500. XLV's forward P/E ratio has risen to 19.3 times, slightly above the overall S&P 500 level. A year ago, the sector still traded at a 25% valuation discount to the S&P 500. Investors are using healthcare stocks to hedge against the risk of an AI trade collapse, with capital shifting from highly volatile tech stocks to defensive sectors. Johnson & Johnson expects to achieve double-digit sales growth by the end of this decade, and Eli Lilly's sales are expected to grow by more than 30% this year. Together, the two account for about 25% of XLV's weight.
Topics
Body · AI translation
The strong rebound in the healthcare sector is sending an unsettling signal to the entire market.
The healthcare sector has recently jumped to become one of the best-performing sectors in the S&P 500. Last week, as concerns about an AI bubble continued to heat up, the sector's valuation discount relative to the S&P 500 disappeared entirely—the forward price-to-earnings ratio of the Health Care Select Sector SPDR ETF (XLV) rose to 19.3 times, slightly above the S&P 500's overall level. Just a year ago, the sector still traded at a 25% valuation discount to the S&P 500. On Monday of this week, XLV rose more than 2% in a single day, with Moderna surging 6.7% and Bristol-Myers Squibb gaining 4.9%.
According to a Wall Street Journal report on the 21st, the logic behind this rally is not complicated: investors are using healthcare stocks to hedge against the risk of an AI trade collapse. Concerns that rising interest rates could suppress AI capital spending are driving money away from highly volatile tech stocks and toward defensive sectors with more stable earnings and weaker cyclicality. Historically, the healthcare sector has tended to outperform the broader market in environments such as tightening credit and the bursting of tech bubbles, and this characteristic is once again drawing market attention.
However, the strength in healthcare stocks is itself a warning signal—it means that more and more investors are starting to buy "insurance" against downside market risk.
The valuation discount disappears: a dramatic reversal within a year
For several years, the healthcare sector has long been in the market's "discount zone." Drug pricing pressure persisted under both the Biden and Trump administrations, soaring medical costs for insurers deterred investors, and with the AI trade dominating market style, healthcare stocks were at one point widely shunned.
A year ago, the sector's discount to the S&P 500 was as high as 25%. Now, that discount has fallen to zero. According to FactSet data, XLV currently has a forward price-to-earnings ratio of 19.3 times, slightly above the S&P 500's overall level. This is the first time in recent years that the healthcare sector has regained a valuation premium.
Asad Haider, head of U.S. healthcare research at Goldman Sachs, noted that the healthcare sector can typically sustain a valuation premium only when three conditions are met simultaneously: investors remain confident in healthcare innovation, they are concerned about the sustainability of earnings in other sectors, and policy-level uncertainty is relatively contained. He believes that all three conditions are now basically in place.
Historically, periods in which the healthcare sector has sustained a valuation premium have been rare, concentrated mainly in two phases: 2003 to 2007 and 2013 to 2015. It also briefly appeared during the surge in inflation and the Federal Reserve's aggressive rate hikes at the end of 2022, but lasted only a short time.
The experience of the mid-2000s is the most valuable historical parallel for the current situation. At that time, geopolitical conflict in the Middle East pushed energy prices higher, the Federal Reserve kept raising rates, and the housing market boom was supporting overall economic profits—highly similar to today's AI-driven boom. During that period, the S&P 500's forward price-to-earnings ratio fell from about 18 times in 2004 to about 15 times in 2007, while the healthcare sector, thanks to more stable earnings, consistently maintained a valuation premium.
What the two eras share is this: against the backdrop of persistently rising debt costs, the market harbors deep-rooted doubts about whether the boom can last.
Fundamental support: clear growth prospects for leading companies
The return of the valuation premium is not supported by defensive logic alone; the fundamentals of some leading companies also provide strong backing.
Haider noted that Johnson & Johnson is expected to achieve double-digit sales growth by the end of this decade; Eli Lilly, benefiting from strong demand for its diabetes and obesity drugs Mounjaro and Zepbound, is expected to see sales grow more than 30% this year. Together, these two companies account for about 25% of the weight of the XLV healthcare ETF, giving them a pivotal influence on the sector's overall valuation.
Policy-level changes have also provided some support for the healthcare sector. According to the Wall Street Journal, more than ten pharmaceutical companies have reached agreements with the Trump administration, trading price concessions for tariff exemptions. At the same time, if Democrats win at least one chamber in next month's congressional elections, a divided government would greatly reduce the likelihood of major new legislation before the 2028 election.
However, divergence within the sector is pronounced. Insurers still face relatively high uncertainty. Jared Holz, a healthcare strategist at Mizuho, said that as the 2028 primaries approach, discussion of "Medicare for All" could heat up again, which would put pressure on companies such as UnitedHealth Group and Humana. By contrast, the policy environment facing drugmakers and medical device makers is arguably the calmest it has been in years.
However, this "insurance policy" is not without its costs
According to reports, the defensive nature of the healthcare sector does not mean zero risk. Investors who rotated into healthcare stocks in early 2006 underperformed the broader market for nearly two years afterward. It was not until the financial crisis erupted that the healthcare sector truly demonstrated its downside resilience—falling far less than the overall market and then outperforming it for a decade, while the sectors that had led the bull market took years to recover.
The core question now is: will AI become this cycle's "housing bubble"? If the answer is yes, then even buying healthcare stocks at a valuation slightly above the market's may, in hindsight, prove to be a bargain. But if the AI boom continues, investors who retreated early into defensive sectors will pay an opportunity cost.
No one can predict when the music in the market will stop. But the unusual moves in the healthcare sector have already told investors one thing clearly: more and more people are quietly preparing for the worst. Risk disclosure and disclaimer
Markets carry risk, and investing requires caution. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are appropriate for their particular circumstances. Any investment made on this basis is at the user's own risk.